Loading company…
Zacharon develops glycan-based therapeutics for lysosomal storage diseases and other conditions.
Zacharon develops small molecule therapeutics targeting glycans, with research focused on lysosomal storage diseases, rare cancers, and inflammatory conditions. Founded in 2004, it was based in San Diego, US. BioMarin Pharmaceutical Inc. acquired the company in January 2012 for USD 10 mn, with possible additional milestone payments.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in